News

News

5/24/23 – ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs

May 24, 2023

4/5/23 – RespireRx Pharmaceuticals Inc. Establishes Research Collaboration with University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders

April 5, 2023

4/3/23 – RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation

April 3, 2023

3/28/23 – RespireRx Pharmaceuticals Inc. Announces the Appointment of Joseph Siegelbaum as an Independent Member of the Board of Directors

March 28, 2023

3/1/23 – ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd

March 1, 2023

2/1/23 – ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits

February 1, 2023

1/23/23 – RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois

January 23, 2023

1/12/23 – RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform

January 23, 2023

12/5/22 – RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development

December 5, 2022

11/17/22 – RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Sleep Apnea

November 17, 2022

11/10/22 – RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4

November 10, 2022

11/7/22 – RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa is an Invited Speaker at the 5th Meridian Drug Discovery Summit

November 8, 2022

9/7/22 – ResolutionRx Slide Deck Re-Purposing Dronabinol

September 25, 2022

8/8/22 – RespireRx Pharmaceuticals Inc. Announces that Sleep Review has Discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition

August 8, 2022

5/24/22 – RespireRx Pharmaceuticals Inc. Announces that Dr. Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals Summit

May 24, 2022

5/17/22 – RespireRx Pharmaceuticals Inc. Announces RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics

May 17, 2022

5/16/22 – RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus

May 16, 2022

3/29/22 – WATCH: RespireRx Interim CEO Discusses Provisional Application for a Novel Lipid-Based Formulation Technology (LFT)

March 29, 2022

3/24/2022 – Media Coverage: RespireRx Pharmaceuticals files provisional patent that may improve solubility of poorly soluble drugs

March 24, 2022

3/23/2022 – RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol

March 23, 2022

3/17/22 – Media Coverage: RespireRx Pharmaceuticals newest GABAkine

March 17, 2022

3/16/22 – RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality

March 16, 2022

3/10/22 – Proactive Investors: RespireRx Pharmaceuticals is developing innovative and revolutionary treatments to combat neuronal signaling disorders

March 10, 2022

3/7/22 – Proactive Investors: RespireRx Pharmaceuticals CEO announces internal restructuring, plans further clinical trials in 2022

March 10, 2022

3/7/2022 – Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward

March 7, 2022

1/24/2022 – RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmacoresistant Epilepsy and Chronic Pain

January 24, 2022

12/14/2021 – RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase

December 14, 2021

12/6/2021 – RespireRx Pharmaceuticals Inc. Announces Publication of Review Article Describing Advances in the Discovery, Development and Commercialization of GABAkines, Including KRM-II-81

December 6, 2021

11/30/2021 – RespireRx Pharmaceuticals Inc. Announces Publication of Book Chapter Describing Novel Analgesic Properties of KRM-II-81

November 30, 2021

11/29/2021 – RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury

November 29, 2021

11/22/2021 – RespireRx Pharmaceuticals Inc. Announces CEO’s OTC Venture Market Podcast

November 22, 2021

WATCH: RespireRx CFO Jeff Margolis Discusses Clinical Pipeline with Proactive Investors

November 4, 2021

RespireRx Pharmaceuticals (OTCQB:RSPI) CFO Jeff Margolis tells Proactive the Glen Rock, New Jersey-based group is advancing its slew of therapeutics throughout the clinical pipeline including a synthetic form of cannabinoid called dronabinol. Margolis says it aims to move to a Phase 3 clinical study to treat obstructive sleep apnea (OSA) with dronabinol. Meanwhile, Margolis says…

11/4/2021 – RespireRx Pharmaceuticals Inc. Announces Video Interview of CFO

November 4, 2021

6/8/2021 – RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference

June 8, 2021

5/12/2021 – RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal Cord Injury

May 12, 2021

4/22/2021 – RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs

April 22, 2021